Trials / Conditions / Unresectable Colorectal Carcinoma

Unresectable Colorectal Carcinoma

13 registered clinical trials studyying Unresectable Colorectal Carcinoma — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix NCT07271355	City of Hope Medical Center	Phase 3
Withdrawn	STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256	City of Hope Medical Center	Phase 1
Withdrawn	Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) NCT05518032	Roswell Park Cancer Institute	Phase 2
Recruiting	LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia NCT06073431	University of Rochester	—
Recruiting	Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for NCT05803382	National Cancer Institute (NCI)	Phase 1
Recruiting	Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Al NCT05863195	ECOG-ACRIN Cancer Research Group	Phase 3
Withdrawn	Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer NCT04119830	Roswell Park Cancer Institute	Phase 2
Recruiting	Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastat NCT04616183	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Unknown	Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations NCT04096417	Academic and Community Cancer Research United	Phase 2
Active Not Recruiting	Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type C NCT03992456	Academic and Community Cancer Research United	Phase 2
Completed	TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Ca NCT04109924	Roswell Park Cancer Institute	Phase 2
Active Not Recruiting	M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Rem NCT02595931	National Cancer Institute (NCI)	Phase 1